Current Report Filing (8-k)
May 19 2017 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19,
2017
CERULEAN PHARMA INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-36395
|
|
20-4139823
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
35 Gatehouse Drive
Waltham, MA
|
|
|
|
02451
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
Registrants Telephone Number, Including Area Code: (781) 996-4300
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 3.01. Notice of Delisting or Failure to
Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On May 19, 2017, Cerulean Pharma Inc. (the Company) received written
notification from the NASDAQ Stock Market (NASDAQ) indicating that based on the Companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, the Companys stockholders equity was $7,741,000, and
therefore, the Company was not in compliance with NASDAQ Listing Rule 5450(b)(1)(A), which requires a $10,000,000 minimum stockholders equity standard. In accordance with such notice, NASDAQ is reviewing the Companys eligibility for
continued listing on the NASDAQ Global Market. The Company has been requested to either provide to NASDAQ, on or before July 3, 2017, its specific plan to achieve and sustain compliance with all NASDAQ Global Market listing requirements and the
Companys time frame to complete its plan or to apply to transfer the Companys securities to the NASDAQ Capital Market. If the Company submits a plan to achieve compliance with the NASDAQ Global Market listing requirements, and after
completion of the review process, NASDAQ determines that such plan is not sufficient, it will provide written notification that the Companys securities will be delisted. At that time, the Company may appeal the NASDAQ Staffs
determination to a NASDAQ Listing Qualifications Panel. If the Company applies to transfer its securities to the NASDAQ Capital Market, it will need to meet the NASDAQ Capital Markets continued listing requirements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
CERULEAN PHARMA INC.
|
|
|
|
|
Date: May 19, 2017
|
|
|
|
By:
|
|
/s/ Christopher D.T. Guiffre
|
|
|
|
|
|
|
|
|
Christopher D.T. Guiffre
President and Chief
Executive Officer
|
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Sep 2023 to Sep 2024